Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
Want to see IN:AUROPHARMA full AI Analyst Report?
AUROPHARMA Stock Chart & Stats
₹1207.35
-₹25.45(-1.99%)
At close: 4:00 PM EST
₹1207.35
-₹25.45(-1.99%)
Day’s Range― - ―
52-Week Range₹1,017.00 - ₹1,550.00
Previous CloseN/A
Volume696.31K
Average Volume (3M)40.80K
Market Cap
₹833.83B
Enterprise Value₹813.68B
Total Cash (Recent Filing)₹88.92B
Total Debt (Recent Filing)₹77.94B
Price to Earnings (P/E)23.6
Beta0.70
Next Earnings
Aug 06, 2026EPS Estimate
14.81Next Dividend Ex-DateN/A
Dividend Yield0.33%
Share Statistics
EPS (TTM)58.93
Shares Outstanding580,801,640
10 Day Avg. Volume31,329
30 Day Avg. Volume40,801
Financial Highlights & Ratios
PEG Ratio24.40
Price to Book (P/B)2.00
Price to Sales (P/S)2.25
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)76.17
Revenue Forecast (FY)₹387.14B
Bulls Say, Bears Say
Bulls Say
Conservative LeverageA lower debt-to-equity and strengthening balance sheet provide durable financial flexibility: eases refinancing risk, supports investment in manufacturing capacity and regulatory compliance, and lets management pursue launches or absorb pricing shocks without forcing asset sales.
Material Free Cash Flow RecoveryA sharp FCF rebound strengthens the company’s ability to fund capex, maintain facilities, and self-finance product launches. Sustained positive FCF improves strategic optionality over months, reducing reliance on external funding for growth or working-capital needs.
Diverse Products & Regulated-market PresenceBroad finished-dosage and API mix plus access to regulated U.S./EU markets provides structural resilience: diversification across geographies and product types cushions volume or price shocks in any single segment and supports long-term market access and revenue stability.
Bears Say
Margin CompressionA sustained drop in gross margins signals structural pricing pressure or cost escalation in core generics/API operations. Lower gross margins erode operating leverage, reduce funds available for reinvestment, and can materially compress future profit potential if persistent.
Moderate, Declining ReturnsDeclining ROE indicates the company is generating only modest returns on shareholder capital. Persistently moderate ROE constrains the ability to compound shareholder value, limits reinvestment upside, and may pressure strategic choices around capital allocation over months.
Volatile Cash Conversion HistoryDespite 2026 improvement, past negative FCF and relatively low cash-to-revenue coverage point to uneven cash conversion. This volatility can constrain consistent capex, debt servicing, or sustained buybacks/dividends, and raises execution risk during industry headwinds.
Aurobindo Pharma Ltd News
AUROPHARMA FAQ
What was Aurobindo Pharma Ltd’s price range in the past 12 months?
Aurobindo Pharma Ltd lowest stock price was ₹1017.00 and its highest was ₹1550.00 in the past 12 months.
What is Aurobindo Pharma Ltd’s market cap?
Aurobindo Pharma Ltd’s market cap is ₹833.83B.
When is Aurobindo Pharma Ltd’s upcoming earnings report date?
Aurobindo Pharma Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 68 days.
How were Aurobindo Pharma Ltd’s earnings last quarter?
Aurobindo Pharma Ltd released its earnings results on May 21, 2026. The company reported ₹15.86 earnings per share for the quarter, missing the consensus estimate of ₹16.331 by -₹0.471.
Is Aurobindo Pharma Ltd overvalued?
According to Wall Street analysts Aurobindo Pharma Ltd’s price is currently Overvalued.
Does Aurobindo Pharma Ltd pay dividends?
Aurobindo Pharma Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.33%. See more information on Aurobindo Pharma Ltd dividends here
What is Aurobindo Pharma Ltd’s EPS estimate?
Aurobindo Pharma Ltd’s EPS estimate is 14.81.
How many shares outstanding does Aurobindo Pharma Ltd have?
Aurobindo Pharma Ltd has 580,801,640 shares outstanding.
What happened to Aurobindo Pharma Ltd’s price movement after its last earnings report?
Aurobindo Pharma Ltd reported an EPS of ₹15.86 in its last earnings report, missing expectations of ₹16.331. Following the earnings report the stock price went up 1.881%.
Which hedge fund is a major shareholder of Aurobindo Pharma Ltd?
Currently, no hedge funds are holding shares in IN:AUROPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aurobindo Pharma Ltd
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
Laurus Labs Ltd.
―
Lupin Limited
―
Zydus Lifesciences Limited
―